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Chapter 1 Introduction 
 
 
1.1 Background 
 
As a leading cause of death and an increasing health burden worldwide, 
myocardial infarction (MI) remains one of the most important clinical 
entities. After the onset of MI, the left ventricle (LV) undergoes a 
continuum of molecular, cellular, and extracellular responses that result in 
LV wall thinning, dilatation, and dysfunction (Thygesen et al., 2012). The 
cardiac healing and remodeling process after MI can be divided into four 
phases: the death of cardiomyocytes, acute inflammation, the formation of 
granulation tissue, and scar formation (Figure 1). Acute inflammation 
usually occurs just after the onset of myocardial infarction. During this 
phase, neutrophils and monocytes are recruited into necrotic tissue, and 
they release inflammatory cytokines and matrix metalloproteinase (MMP) 
(Liehn et al., 2011). Inflammatory cell infiltration and MMP production 
play important roles in the degradation of necrotic debris and the 
subsequent scar formation. However, excess inflammatory response and 
MMP overproduction are likely to induce adverse cardiac remodeling, 
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leading to left ventricular dilatation, dysfunction, and cardiac rupture 
(Frangogiannis, 2015; Matsui et al., 2010). Despite the significant progress 
made on therapeutic strategies for MI in last few decades, mortality and 
morbidity remain high, and adverse cardiac remodeling after MI remains a 
critical issue to be solved. Therefore, continuous improvement in 
medications for the disease is still a major concern in global medical 
research. 
Nuclear receptors (NRs) are members of a large superfamily and 
widely considered as ligand-activated transcriptional factors. These were 
originally found within cells that are responsible for sensing steroid and 
thyroid hormones and certain other molecules, and work with other 
proteins to regulate the expression of specific genes, thereby controlling the 
development, homeostasis, and metabolism of the organism (Chambon, 
2005; Evans, 2005). Nuclear receptors represent one of the most important 
targets for therapeutic drug development, and many compounds targeted 
for nuclear receptors have already been developed as marketable drugs, e.g. 
peroxisome proliferator-activated receptor α and γ activators.  
Rev-erb belongs to a nuclear receptor superfamily, and contains two 
subgroups, Rev-erb α (NR1D1) and β (NR1D2). Rev-erb α is highly 
expressed in the liver, skeletal muscle, adipose tissue, heart and brain, 
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participating in the development and circadian regulation of these tissues. 
(Solt et al., 2012). Rev-erb β displays a similar structure and has been 
implicated in the control of lipid and glucose metabolism and circadian 
rhythm, collaborating extensively with Rev-erb α (Bugge et al., 2012). 
Heme was identified as a physiological ligand for Rev-erb receptor, which 
regulates their transcriptional activity (Figure 2). Moreover, Rev-erb α 
displays a hydrophobic interface that binds the corepressor N-CoR, making 
it a potent transcriptional repressor (Solt et al., 2012; Woldt et al., 2013). 
Previous studies reported Rev-erb α regulated mitochondrial biogenesis in 
loss- and gain-of-function settings. Rev-erb α deficiency in skeletal muscle 
resulted in reduced mitochondrial content and ATP production through 
deactivating AMPK-SIRT1–PGC1 signaling pathway (Woldt et al., 2103). 
Recently, SR9009 and SR9011 were developed as synthetic Rev-erb 
agonists, which facilitates Rev-erb α to recruit its corepressor NCoR and 
repress downstream targets (Solt et al., 2012). From the results of the 
previous studies using agonists, it has been identified that the nuclear 
receptor Rev-erb α plays a pivotal role in the modulation of skeletal muscle 
oxidative capacity by regulating mitochondrial biogenesis and autophagy, 
leading to increasing in exercise capacity (Woldt et al., 2013). Moreover, 
long-term treatment with SR9009 was shown to reduce atherosclerotic 
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plaque by decreasing the ratio of proinflammatory M1 macrophages to 
anti-inflammatory M2 macrophages in low-density lipoprotein (LDL) 
receptor-deficient mice fed a Western diet (Sitaula et al., 2015). Therefore, 
Rev-erb is expected to be a promising therapeutic target for metabolic 
syndrome and atherosclerotic disease. However, little is known about the 
Rev-erb agonist effect on the progression of MI and heart failure. 
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Figure 1. Phases of cardiac healing and remodeling process after MI: 
(1) death of cardiomyocytes; (2) acute inflammation; (3) formation of 
granulation tissue; and (4) scar formation. 
Death of cardiomyocytes starts at approximately 1 h after coronary 
artery occlusion, and can either be the result of apoptosis or necrosis. 
During acute inflammation, the influx of inflammatory cells, including 
neutrophils and monocytes, for phagocytosis and removal of dead 
cardiomyocytes into the infarcted area and degradation of the 
extracellular matrix (ECM) by matrix metalloproteinase (MMP) takes 
place between 1 h and 4 d after MI. MMP also modulates inflammatory 
cytokine and chemokine activity. Generation of matrix fragments exerts 
potent inflammatory effects. Thereafter, formation of granulation tissue, 
characterized by the presence of fibroblasts, macrophages, 
myofibroblasts, new blood vessels, and ECM proteins, occurs in the 
infarcted heart between 2 and 14 d after MI. To rescue the loss of the 
shielding effects of the normal matrix, fibroblasts and myofibroblasts 
produce ECM. Finally, granulation tissue matures in the infarcted heart 
between 14 d and 2 mo after MI. The scar is characterized by a cross-
linked, collagen-rich region that is induced by lysyl oxidase. In this 
phase, most infarct myofibroblasts undergo apoptosis and disappear. 
The time intervals for each phase are dependent on the species. (Matsui 
et al., 2010) 
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Figure 2. Schematic of Rev-erb α receptor.  
Heme was identified as a physiological ligand for Rev-erb receptor.  
Recently, SR9009 is developed as a synthetic Rev-erb agonist. The 
nuclear receptor Rev-erb α plays a key role in (1) regulation of 
circadian rhythm (2) modulation of skeletal muscle oxidative capacity 
by regulating mitochondrial biogenesis and autophagy, and (3) 
modulation of inflammatory response through macrophage infiltration.  
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1.2   Objective 
 
This study was aimed to clarify the roles of Rev-erb in post-MI remodeling 
and the effects of Rev-erb agonist SR9009 on cardiac function and survival 
after MI. 
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Chapter 2 Methods 
 
 
2.1 Mouse Model 
 
After receiving approval from the Institutional Animal Experiment 
Committee of the University of Tsukuba, animal experiments were carried 
out humanely and in accordance with the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health, the 
Regulation for Animal Experiments in our university, and the Fundamental 
Guideline for Proper Conduct of Animal Experiment and Related Activities 
in Academic Research Institutions under the jurisdiction of the Ministry of 
Education, Culture, Sports, Science and Technology of Japan. 
We used 165 male wild-type C57BL6 mice purchased from CLEA 
Japan, Inc. (Tokyo, Japan) in total. At 12-14 weeks of age, mice were 
anesthetized with ketamine and xylazine, followed by tracheal intubation 
and artificial ventilation (MiniVent 845; Harvard Apparatus, Holliston, 
MA, USA). Next, a thoracotomy was performed to expose the heart, and 
MI was induced by the permanent ligation of the left anterior descending 
coronary artery (LAD) with 7-0 polypropylene suture passed about 1 mm 
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from the inferior margin of the left atrial auricle. MI was confirmed by 
visual observation of myocardial color change and ST-segment elevation 
on the electrocardiogram recording. The sham-operated group was 
subjected to a similar procedure without ligation of the coronary artery. 
After closure of the thorax and recovery of spontaneous breathing, the mice 
were extubated and placed in a new box on the warm pad for recovery 
(Figure 3). Study period was within 2 weeks after surgery, and mice were 
monitored daily during the study. Among 165 mice used for all 
experiments, 58 mice died before sacrifice (40 mice died due to heart 
failure and/or arrhythmia including operational death, and 18 died due to 
cardiac rupture). If mice showed body weight loss of more than 20% and/or 
significant clinical signs due to the development of heart failure (e.g., 
increased respiratory rates, reduced activity, piloerection, hunched posture), 
they were immediately euthanized by intraperitoneal injection of 200 
mg/kg sodium pentobarbital.  Four mice were euthanized because of 
cardio-respiratory distress (weakness, fatigue, deep breathing, dyspnea). 
Thus, euthanized mice were considered as death due to heart failure.  
SR9009 was purchased from Merck Millipore (Darmstadt, Germany) 
and was dissolved in 1% dimethyl sulfoxide (DMSO) in normal saline. 
SR9009 could administrated via injection or oral and no side effect are 
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reported. We started intraperitoneal administration with SR9009 (100 
mg/kg/day or vehicle (1% DMSO in normal saline) from 1 day before 
surgery. Consequently, mice were divided into four groups: sham-operated 
mice treated with vehicle (Sham+V), sham-operated mice treated with 
SR9009 (Sham+SR), MI mice treated with vehicle (MI+V), and MI mice 
treated with SR9009 (MI+SR). The selection of the doses was based on the 
previous study and displayed no apparent toxicity (Sitaula et al., 2015). We 
first investigated mortality over the 14 days after MI and performed 
echocardiography at 7 days after MI and just before sacrifice. Next, we 
excised and collected the hearts of the mice sacrificed at 3 and 7 days after 
surgery for RNA extraction and histochemical analysis, and those of the 
mice sacrificed at 1 and 5 days after surgery for flow cytometric analysis 
(Figure 4).  
 
2.2  Echocardiography 
 
This study obtained echocardiographic images from the parasternal long-
axis view and short-axis view at the papillary muscle level under anesthesia 
with isoflurane using a Doppler echocardiographic system (Vevo 2100; 
Visual Sonics, Toronto, Canada). Accordingly, we determined the heart 
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rate, left ventricular (LV) end-diastolic diameter (LVDd), LV end-systolic 
diameter (LVDs), fractional shortening (FS), LV ejection fraction (LVEF), 
interventricular septal thickness (IVST), posterior wall thickness (PWT) 
and LV mass. EF was calculated by the Teichholz method. 
 
2.3  RNA Gene Expression 
 
RNA extraction and gene expression analysis were performed as previously 
described with minor modifications (Xu et al., 2012). In brief, total RNA 
was extracted from the LV tissues using a RNeasy Fibrous Tissue Mini Kit 
(Qiagen, Venlo, Netherlands), and 2 μg of total RNA was reverse 
transcribed to cDNA with a High-Capacity cDNA Reverse Transcription 
Kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA). The mRNA 
expression levels of the target genes were analyzed by an ABI Prism 7500 
sequence detection system (Thermo Fisher Scientific). The commercially 
available gene-specific primers and probe sets were obtained from 
Integrated DNA Technologies (Coralville, IA, USA). The PCR mixture (10 
μl total volume) consisted of primer and probe for each gene at 250 nM, 
and PrimeTime Gene Expression Master Mix (Integrated DNA 
Technologies). PCR amplification was performed in duplicate as follows: 1 
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cycle at 95°C for 10 min and 40 cycles at 94°C for 15 s and 60°C for 1 
min. The primer and probe used in the study are mentioned as follows: 
Nr1d1 (Mm.PT.58.17472803), Nr1d2 (Mm.PT.58.31165809), Nppb 
(Mm.PT.58.8584045.g), Il6 (Mm.PT.58.10005566), Mcp1 
(Mm.PT.58.42151692), Ly6g (Mm.PT.58.30498043), Itgam (Cd11b) 
(Mm.PT.5814195622), Mmp9 (Mm.PT.58.10100097), Col1a1 
(Mm.PT.58.756.2513), Col3a1 (Mm.PT.58.13848686). The quantitative 
values of target mRNA were normalized by 18S rRNA (4319413E, Thermo 
Fisher Scientific) expression. The results were obtained from 2-3 
independent measurements (n=4 in each group) performed in duplicate. 
 
2.4  Enzyme Immunoassay (EIA) for BNP 
 
Plasma BNP concentration was measured by using a Brain Natriuretic 
Peptide EIA Kit (RAB0386-1KT, Sigma-Aldorich, Inc., St. Luise, MO, 
USA) according to the procedural manual. In brief, the samples and 
standards mixed with 10 pg/ml of biotinylated BNP peptide were added to 
the anti-BNP antibody-immobilized plate, where the biotinylated BNP 
peptide competed with unlabeled (endogenous) BNP for binding to the 
antibody. After incubating plate at 4°C overnight and washing wells, 
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horseradish peroxidase (HRP)-streptavidin solution was added to each well, 
and incubated for 45 minutes at room temperature. After washing, 
tetramethylbenzidine (TMB) solution was then added to each well to 
visualize the immunoreaction. After adding stop solution, absorbance of 
each well was measured by using Varioskan LUX microplate reader 
(ThermoFisher) at 450nm. The result was obtained from one measurement 
(n=4 in each group) performed in duplicate. 
  
2.5 Histology and Immunofluorescence 
 
The hearts were fixed with 4% paraformaldehyde, embedded in paraffin, 
sectioned into 4-μm-thick slices, and stained with Masson’s trichrome. 
Images were obtained by a digital microscope (Biozero BZ-X700; Keyence, 
Osaka, Japan), and collagen deposition was calculated by dividing the 
collagen depositing area to the total area. The analysis was performed using 
ImageJ analysis software (Ver. 1.45, NIH, USA). 
To evaluate the expression of MMP9 and Rev-erb α, we performed 
immunofluorescence. After deparaffinization and antigen activation, 
sections were incubated with polyclonal rabbit anti-MMP9 (ab38898; 
Abcam, Cambridge, UK) or Rev-erb α (sc-100910, Santa Cruz 
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Biotechnology, Inc, Dallas, TX, USA) antibodies at 4°C overnight. Next, 
sections were sufficiently rinsed in PBS and then incubated to Alexa Fluor 
594-labeled goat anti-rabbit IgG or Alexa Fluor 488-labeled goat anti-
mouse IgG (Thermo Fisher Scientific) at room temperature for 2 hours. 
After rinsing in PBS and mounting on slides with mounting medium with 
DAPI, the fluorescent images were captured by a digital fluorescent 
microscope (Biozero BZ-X700). The ratio of Alexa Fluora 594-positive 
area to total area was calculated with the ImageJ analysis software. 
 
2.6  Flow Cytometry 
 
Heart inflammatory cells were isolated and processed as described 
previously (Machino-Ohtsuka et al., 2014). In brief, 1 and 5 days after MI 
or sham operation, hearts were excised, cut roughly, and dissociated by 
using gentleMACS Dissociator (Miltenyi Biotec, Bergisch Gladbach, 
Germany) in HBSS mixed with hyaluronidase, collagenase, and DNase I in 
accordance with the experimental protocol. Next, the cells were rinsed with 
PBS, dissolved with MACS buffer (Miltenyi Biotec), and passed through 
cell strainer (70µm) (Corning Inc., Corning, NY, USA). After removing red 
blood cells by ACK buffer, the cells were directly stained with 
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fluorescence-conjugated antibodies as follows: FITC-conjugated anti-
mouse Ly6g antibody, PE-conjugated anti-mouse CD11b antibody, and 
APC-conjugated anti-mouse CD45.2 antibody. To differentially investigate 
M1/M2 macrophages, the cells collected from mice 5 days after surgery 
were also stained with FITC-conjugated anti-mouse F4/80 antibody, PE-
conjugated anti-mouse CD11b antibody, and APC-conjugated anti-mouse 
CD206 antibody. After 1 hour incubation at 37°, the cells were rinsed with 
PBS, diluted with MACS buffer, mixed with DAPI, and analyzed with a 
FACSCalibur instrument (Becton Dickinson Co., Franklin Lakes, NJ), 
followed by analysis with FlowLogic software (Inivai Technologies, 
Mentone, Victoria, Australia). All antibodies were obtained from Bay 
Bioscience (Brookline MA, USA), Biolegend Inc. (San Diego, CA, USA), 
or Amersham Biosciences Corp. (Buckinghamshire, United Kingdom). 
 
2.7  Western Blotting Analysis 
 
Western blotting was performed as described previously (Xu et al., 2012). 
In brief, isolated LVs were homogenized in PRO-PREP protein extraction 
solution (iNtRON Biotechnology, Inc. Kyungki-Do, Korea), and the 
supernatants were used for western immunoblotting. Appropriate volumes 
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of the samples (10 μg) were mixed with an equal volume of sample buffer, 
heated at 95°C for 5 min, and then subjected to SDS-PAGE using 4-15% 
gradient polyacrylamide gels (Bio-Rad Laboratory, Hercules, CA, USA). 
The proteins were transferred by semidry electroblotting from gels to 
polyvinylidene difluoride membranes. The blots were then blocked with the 
primary antibodies as follows: phospho-NF-κB p65 (Ser536 (#3033) and 
Ser468 (#3039)), NF-κB (L8F6) (#6956), phospho-p38 (Thr180/182) 
(#9211S), p38 mitogen activated protein kinase (MAPK) (#9212), 
phospho-p44/42 MAPK (Thr202/Thr204) (#9101S), p44/42 MAPK 
(#9102), β-actin (#4967) (all were purchased from Cell Signaling 
Technology, Inc., Danvers, MA, USA), and Rev-erb α (RS-14) (sc-100910, 
Santa Cruz Biotechnology, Inc, Dallas, TX, USA). The blots were 
incubated with an appropriate second antibody, horseradish peroxidase 
(HRP)-conjugated goat anti-rabbit IgG (ab6721, Abcam) or HRP-
conjugated rabbit anti-mouse IgG (ab97046, Abcam). Immunoreactions 
were visualized with an enhanced chemiluminescence method (ECL Prime 
Western Blotting Detection; GE Healthcare, Southeast, UK). Densitometric 
analysis was performed on scanned immunoblot images with the ImageJ 
analysis software. The ratios of densities of bands detected by using 
phosphorylated antibodies to those detected by using nonphosphorylated 
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(total) antibodies or β-actin antibody was obtained from 2-3 independent 
measurements (n = 3 per group for each measurement). 
 
2.8  Statistical Analysis 
 
All data are expressed as means ± SEM. Experimental groups were 
compared by one-way analysis of variance followed by Bonferroni’s test 
for multiple comparisons. When the results were not normally distributed, 
statistical analyses were performed using Kruskal-Wallis one-way analysis 
of variance. The effect of SR9009 on the survival of mice was analyzed by 
Kaplan-Meier methods and compared by log-rank test. Differences were 
considered statistically significant at p < 0.05. The analysis was performed 
using IBM SPSS version 21.0 software (IBM Co., Armonk, NY, USA). 
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Figure 3. Animals model and study protocol. 
Intraperitoneal administration with SR9009 (100 mg/kg/day or vehicle 
(1% DMSO in normal saline) was started on 1 day before surgery. Mice 
were divided into four groups: 1) sham-operated mice treated with 
vehicle (Sham+V), 2) sham-operated mice treated with SR9009 
(Sham+SR), 3) MI mice treated with vehicle (MI+V), and 4) MI mice 
treated with SR9009 (MI+SR). MI was induced by the permanent 
ligation of the left anterior descending coronary artery (LAD) with 7-0 
polypropylene suture passed about 1 mm from the inferior margin of 
the left atrial auricle. MI was confirmed by visual observation of 
myocardial color change and ST-segment elevation on the 
electrocardiogram recording. The sham-operated group was subjected 
to a similar procedure without ligation of the coronary artery. 
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Figure 4. Assesment protocol. 
Survival rate was monitored over the 14 days after MI. 
Echocardiographic analysis was performed on 7 days after surgery. For 
RT-PCR, western blotting, and immunofluorescence, hearts were 
collected on 3 and 7 days after surgery. For flow cytometry, hearts were 
collected on 1 and 5 days after surgery. 
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Chapter 3 Results 
 
 
3.1 Gene and protein expression levels of Rev-erb in the LVs after 
MI 
 
First, we investigated the gene and protein expressions of Rev-erb in the 
LVs after MI. The mRNA expression level of Rev-erb α in the LVs was 
slightly changed but not significantly different between sham, day 3, and 
day 7 after MI (Figure 5A). Moreover, the expression level of Rev-erb β 
mRNA in the LV was significantly decreased 3 and 7 days after MI (Figure 
5B).  
The protein expression level of Rev-erb α was slightly increased on day 3 
whereas it was significantly decreased on day 7 after MI (Figure 6).  
 
Figure 5. mRNA expression levels of Rev-erb α (A) and β (B) in the left 
ventricular border area after myocardial infarction.  
B A 
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(A) The expression level of Rev-erb α mRNA in the LV was not 
significantly different between sham, 3 days, and 7 days after MI (n=4 
animals for each time point). (B) The expression level of Rev-erb β 
mRNA in the LV was significantly decreased 3 and 7 days after MI 
(n=4 animals for each time point). The bar graphs show the group 
mean±SEM. *p<0.05 vs Sham. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Protein expression level of Rev-erb α in the in the left 
ventricular border area after myocardial infarction.  
Western blotting analysis showed a significant decrease in the 
expression level of Rev-erb α 7 days after MI (n=3 animals for each 
time point). The bar graphs show the group mean±SEM. *p<0.05 vs 
Sham.  
 
3.2 Survival rate after MI 
 
We evaluated survival after MI with or without SR9009 treatment. After 
permanent ligation of the LAD in 58 mice (38 in MI+V; 20 in MI+SR), 18 
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mice (15 in MI+V; 3 in MI+SR) died because of ventricular rupture that 
occurred between 3 and 7 days after MI. Meanwhile, 16 mice (11 in MI+V; 
5 in MI+SR) died without bleeding in the thoracic cavity. We assumed they 
died either due to acute heart failure or cardiac arrhythmia. Survival rate 
was markedly reduced by 31.6% in MI+V. However, it was significantly 
higher in MI+SR (60.0%, at day 14 after myocardial infarction; log-rank 
test, p=0.032 compared between MI+SR and MI+V; Figure 7).  
 
 
Figure 7. Kaplan-Meier survival curves after myocardial infarction. 
Survival rate was significantly higher in MI+SR than in MI+V (60.0% 
vs 31.6% at day 14 after myocardial infarction; log-rank test, p=0.032 
compared between MI+SR and MI+V). 
 
3.3 Echocardiographic analysis  
 
To assess cardiac function after MI, we performed echocardiographic 
 MI+SR 
 MI+V 
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analysis 7 days after surgery in each group (Figure 8). SR9009 treatment 
significantly improved LVEF and FS (Table). LVDd, Ds, and LV mass were 
slightly lower in MI+SR, but these were not significantly different between 
MI+V and MI+SR (Figures 8B-E). 
 
3.4 Body and tissue weights 
 
SR9009 treatment was reported to reduce body weight (BW) in obese mice 
fed with a high-fat diet (Laura et al., 2012); however, there was no 
significant difference in BW between MI+V and MI+SR before and after 
the procedure (Figure 9A). Moreover, the ratio of LV weight to BW and the 
ratio of lung weight to BW were not significantly different between MI+V 
and MI+SR (Table, Figures 9B-C). 
  Sham+V Sham+SR MI+V MI+SR 
  n=4 n=4 n=9 n=7 
BW (g) 24.02±0.62 25.35±0.23 23.77±0.75 23.39±0.83 
LV/BW(mg/g) 4.29±0.05 4.44±0.15 5.42±0.36* 5.35±0.51* 
Lung/BW (mg/g) 5.38±0.21 5.19±0.13 8.25±1.08* 7.20±0.87* 
LVDd (mm) 3.16±0.19 2.78±0.24 5.25±0.21* 4.88±0.26* 
LVDs (mm) 2.13±0.23 1.87±0.30 4.97±0.24* 4.36±0.30* 
FS (%) 31.67±4.74 32.29±4.10 6.23±0.92* 11.07±2.04*† 
EF (%) 64.67±7.66 61.71±6.27 13.85±2.02* 23.78±4.21*† 
IVST (mm) 0.725±0.02 0.69±0.11 0.67±0.06 0.74±0.03 
PWT (mm) 0.62±0.10 0.90±0.07 0.68±0.04 0.60±0.11 
LV Mass (mg) 83.12±12.11 85.72±11.72 156.02±21.33* 147.30±11.64* 
 
Table. Tissue weights and echocardiographic analysis.  
The values are mean + SD. (n=4 in each sham group, n=9 animals in 
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MI+V group, and n=7 animals in MI+SR group). *p<0.05 vs Sham+V; 
†p<0.05 vs MI+V. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 Echocardiographic analysis. 
(A) The representative M-mode findings of echocardiography 7 days 
after MI. LV ejection fraction (EF) (B) was significantly higher in 
MI+SR than in MI+V, whereas LV end-diastolic diameter (LVDd) (C), 
LV end-systolic diameter (LVDs) (D) and LV mass (E) were not 
significantly different between MI+V and MI+SR (n=4 in each sham 
group, n=9 animals in MI+V group, and n=7 animals in MI+SR group). 
*p<0.05 vs Sham+V; †p<0.05 vs MI+V. 
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Figure 9 Body weight and tissue weight.  
Body weight (BW) (A) was decreased after surgery, but not 
significantly different in all groups. The ratio of left ventricular (LV) 
weight to BW (B) and lung weight to BW (C) were also not 
significantly different between MI+V and MI+SR (n=4 in each sham 
group, n=8 animals in MI+V group, and n=7 animals in MI+SR group). 
The bar graphs show the group mean±SEM. *p<0.05 vs Sham+V. 
 
3.5  Histology and collagen deposition 
 
LV size and wall thickness were similar between Sham+V and Sham+SR. 
Although collagen deposition was observed in large areas of the LV of both 
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MI+V and MI+SR, there were no obvious histological differences between 
the two groups (Figures 10A-D). Quantitative analysis revealed that there 
was no significant difference in collagen depositing area between MI+V 
and MI+SR (Figure 10E) LV gene expression levels of Col1a and Col3a 
were markedly upregulated 7 days after MI. SR9009 treatment reduced the 
Col1a expression, but there were no significant differences in mRNA 
expression levels of Col1a and Col3a between MI+V and MI+SR (Figures 
10F-G). 
 
 
Figure 10. Collagen deposition. 
Representative photomicrographs of the left ventricles at papillary 
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muscle level Sham+V (A), Sham+SR (B), MI+V (C), and MI+SR (D).  
(E) The ratio of collagen depositing area to total area. There was no 
significant difference in collagen deposition between MI+V and 
MI+SR (n=4 animals in each group). (F) The mRNA expression level 
of collagen type Ia1 (Col1a) was significantly increased in MI+V, and 
was tend to be decreased in MI+SR, but not significantly different 
between MI+V and MI+SR. (G) The mRNA expression level of 
collagen type IIIa1 (Col3a) was also significantly increased in MI+V, 
and was not significantly different between MI+V and MI+SR (n=4 
animals in each group). *p<0.05 vs Sham+V. Scale bar (1.02 mm) 
 
3.6 Real-time PCR of gene expressions and plasma BNP 
concentration analysis  
 
We next investigated mRNA expression levels on 3 and 7 days after MI in 
the LV by using real-time PCR. The mRNA expression level of natriuretic 
peptide precursor B (Nppb), which encodes a marker of heart failure brain 
natriuretic peptide, was 8-fold higher in MI+V compared to Sham+V, and it 
was significantly lower in MI+SR than in MI+V. Moreover, the left 
ventricular expression levels of inflammatory cytokines Il6 and Mcp1, 
neutrophil-related surface antigen Ly6g, and monocyte/macrophage-related 
surface antigen Cd11b were increased after MI, and these levels were 
dramatically decreased by SR9009 treatment. The mRNA expression levels 
of Mmp9, a major extracellular matrix protein playing a critical role in 
post-MI remodeling, was also increased in MI+V and was significantly 
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decreased in MI+SR compared with MI+V. Moreover, plasma BNP 
concentration on day 7 was also significantly higher in MI+V than in 
Sham+V, and it was significantly lower in MI+SR than in MI+V. These 
results suggested that infiltration of neutrophils and 
monocytes/macrophages, and productions of inflammatory cytokines and 
extracellular matrix were reduced by the treatment with SR9009 during the 
acute phase of MI (Figures 11-12). 
It has been reported that Rev-erb α regulates not only inflammation but 
also metabolic process. Rev-erb α controls mitochondrial biogenesis and 
respiration in the skeletal muscle through the AMPK-SIRT1-PGC-1α- 
TFAM signaling pathway. However, we could not find significant increases 
in the expression level of Tfam1, a gene encoding mitochondrial 
transcriptional factor A, and also in the expression levels of Ppara, Pgc1, 
genes encoding key enzymes of fatty acid metabolism; Pdk4, Glut4, genes 
encoding key enzymes of glucose metabolism; and Bdh1, a gene encoding 
of ketone metabolism, between MI+V and MI+SR 7 days after MI (Figure 
13). 
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Figure 11. Gene expression levels of the left ventricles analyzed by 
real-time PCR on days 3.  
The mRNA expression level of natriuretic peptide precursor B (Nppb) 
was significantly lower in MI-SR than in MI-V (n=4 animals in each 
group). The expression levels of Il6, Mcp1, Ly6g, and Cd11b were 
significantly increased in MI+V and were markedly decreased in 
MI+SR. Matrix metallopeptidase (Mmp)9 was also significantly lower 
in MI-SR than in MI-V. The bar graphs show the group mean±SEM. 
*p<0.05 vs Sham+V; †p<0.05 vs MI+V. 
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Figure 12. Gene expression levels of the left ventricles and plasma BNP 
concentration analyzed on days 7.  
The mRNA expression level of natriuretic peptide precursor B (Nppb) 
was significantly lower in MI-SR than in MI-V (n=4 animals in each 
group). The expression levels of Il6, Mcp1, Ly6g, and Cd11b were 
significantly increased in MI+V and were markedly decreased in 
MI+SR. Matrix metallopeptidase (Mmp)9 was also significantly lower 
in MI-SR than in MI-V. Moreover, Plasma BNP concentration was also 
significantly higher in MI than in sham, and was significantly lower in 
MI+SR than in MI+V. The bar graphs show the group mean±SEM. 
*p<0.05 vs Sham+V; †p<0.05 vs MI+V. 
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Figure 13. Metabolism-related gene expression levels of the left 
ventricles analyzed by real-time PCR.  
There were no significant increases in the expression level of Tfam1, a 
marker of mitochondrial biogenesis, and also Ppara, Pgc1, Pdk4, 
Glut4, Bdh1, the genes encoding key enzymes of fatty acid, glucose, 
and ketone metabolism, between MI+V and MI+SR 7 days after MI. 
The bar graphs show mean±SEM. *p<0.05 vs Sham+V. 
 
 
3.7 Immunofluorescence for Rev-erb α and MMP9 
 
To confirm the protein expression level of Rev-erb α and MMP9 after MI, 
we performed immunofluorescence. Immunofluorescence for Rev-erb α 
showed that green fluorescence-positive nuclei could be detected mainly in 
the cardiomyocytes, and it was reduced after MI (Figure 14). 
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Immunofluorescence intensity for MMP9 could be weakly detected in both 
of the sham groups, and it was enhanced mainly in the interstitial tissue of 
the border area after MI. MI+SR displayed less intensity of MMP9 
compared to that in MI+V (Figure 15). Quantitative analysis revealed that 
significant increase in immunofluorescence-positive area in MI+V was 
reduced by SR9009 treatment. 
 
 
 
Figure 14. Representative immunofluorescence images of the left 
ventricles stained with Rev-erb α.  
Rev-erb α was stained with Alexa Fluor 488 (green), and nuclei were 
stained with DAPI (blue). All images show 40× magnification. Scale 
bar (50 µm).  
      Rev-erb α  x40       Rev-erb α +DAPI  x40 
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Figure 15. Representative immunofluorescence images of the left 
ventricles stained with MMP9.  
MMP9 was stained with Alexa Fluor 594 (red), and nuclei were stained 
with DAPI (blue). All images show 40× magnification. The ratio of 
immunofluorescence-positive area to total area was significantly 
increased in MI+V and was markedly decreased in MI+SR (n=4 
animals in each group). The bar graphs show the group mean±SEM. 
*p<0.05 vs Sham+V; †p<0.05 vs MI+V. Scale bar (50 µm) 
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3.8 Flow cytometry analysis of inflammatory cell infiltration in the 
LV 
 
To further investigate the effect of SR9009 on the infiltration of 
inflammatory cells into the LV during the acute phase of MI, we performed 
flow cytometric analysis. CD45+CD11b+Ly6G+ cells (neutrophils) were 
dramatically increased in the heart 1 day after MI from MI+V compared to 
Sham+V. SR9009 treatment decreased the infiltrations of 
CD45+CD11b+Ly6G+ cells 1 day after MI. Quantitative analysis revealed a 
significant decrease in the percentage of CD45+CD11b+Ly6G+ cells to 
CD45+ cells. These results suggested that neutrophil influx was reduced by 
the treatment with SR9009 during the acute phase. 
This study next investigated the infiltrations of M1/M2 macrophages in 
the heart 5 days after MI. The percentage of CD11b+F4/80+CD206+ cells 
(M2 macrophages) to live cells was not significantly different between 
MI+V and MI+SR 5 days after MI; however, the percentage of 
CD11b+F4/80+CD206- cells (M1 macrophages) to live cells was 
significantly lower in MI+SR than in MI+V (Figure 16). 
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Figure 16. Flow cytometric analysis.  
Flow cytometric analysis of the infiltration of inflammatory cells into 
the infarct and border areas at 1 day after myocardial infarction (MI) 
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(n=5 in each group). The representative plots (gated on CD45+ and 
expanded into Ly6G and CD11b) of Sham+V (A), MI+V (B), and 
MI+SR9009 (C) are shown. The percentage of CD45+CD11b+Ly6G+ 
cells (neutrophils) (D) to CD45+ cells was significantly lower in 
MI+SR than in MI+V, suggesting that neutrophil infiltration was 
reduced by SR9009 treatment. (E-G) Flow cytometric analysis of 
M1/M2 macrophage infiltration into the infarct and border areas at 5 
days after MI (n=5 in each group). The representative plots (gated on 
CD11b and expanded into F4/80 and CD206) of MI+V, and 
MI+SR9009 are shown. The percentage of F4/80+CD206- cells to live 
cells was significantly lower in MI+SR than in MI+V although the 
percentage of F4/80+CD206+ cells to live cells was not significantly 
different between MI+V and MI+SR, suggesting that proinflammatory 
M1 macrophage infiltration was reduced by SR9009 treatment. The bar 
graphs show the group mean±SEM. *p<0.05 vs Sham+V; †p<0.05 vs 
MI+V. 
 
3.9  Western blotting for NF-κB and MAPKs signaling 
 
Rev-erb α has been reported to repress cytokine productions not only 
directly through a Rev-erb α-binding motif but also indirectly through NF-
κB and/or MAPK-signaling pathway (Sato et al., 2014a; Sato et al., 2014b). 
Therefore, we performed western blotting to evaluate whether SR9009 
treatment influenced NF-κB and MAPKs in the LV after MI. SR9009 
treatment suppressed the expression of serine 468-phosphorylated (S468) 
and serine 536-phosphorylated (S536) NF-κB p65 (Figure 17A). 
Quantitative analysis revealed that the ratio of phospho-NF-κB p65 (S468) 
to NF-κB p65 was significantly lower in MI+SR than in MI+V (Figure 
17B). SR9009 treatment also suppressed phosphorylations of p38 and 
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p44/42 (ERK) (Figure 17A). The ratios of phosphorylated p38 to p38 and 
phosphorylated ERK to ERK were significantly lower in MI+SR than in 
MI+V (Figure 17D).  
 
Figure 17. Western blotting analysis.  
(A) Representative images of western blotting for phospho-NF-κB p65 
(S468 and S536), NF-κB, phospho-p38, p38, phospho-ERK, ERK, and 
β-actin. (B) The ratio of phospho-NF-κB (S468) to NF-κB was 
significantly lower in MI+SR than in MI+V. (C) The ratio of phospho-
NF-κB (S536) to NF-κB had a similar tendency, but no significant 
difference. (D) The ratio of phospho-p38 to p38 was significantly lower 
in MI+SR than in MI+V. (E) The ratio of phospho-ERK to ERK was 
also significantly lower in MI+SR than in MI+V. (n=3 animals in each 
group). The bar graphs show the group mean±SEM. *p<0.05 vs 
Sham+V; †p<0.05 vs MI+V.  
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Chapter 4 Discussion 
 
 
In this study, we showed for the first time, to our knowledge, that Rev-erb 
agonist SR9009 improved LV function and survival after MI. Moreover, we 
also showed that Rev-erb agonist decreased Il6 and Mcp1 production, 
Mmp9 expression, NF-κB and MAPKs activations, and neutrophil/M1 
macrophage infiltrations in infarct and border myocardium during the acute 
phase of MI. These results suggested that the pharmacological activation of 
Rev-erb exerts beneficial effects on the acute process of post-MI 
remodeling by strongly inhibiting cytokine production and inflammatory 
cell infiltration into the infarcted heart. 
Inflammatory response after MI is a double-edged sword, and how to 
regulate inflammation to prevent adverse cardiac remodeling is an 
important issue to be considered when developing a new treatment for heart 
failure (Anzai, 2013; Cohn et al., 2000; Weiford, 2005). In the present 
study, we showed that the expression levels of inflammatory cytokines 
including Mcp1 and Il6 were dramatically suppressed by SR9009 treatment 
in the LV during the acute phase of MI, and that of Mmp9 was also 
suppressed by SR9009 treatment. Moreover, we also showed that NF-κB 
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and MAPKs activation were inhibited by the treatment with SR9009. These 
findings are consistent with the previous studies (Gibbs et al., 2011; Lam et 
al., 2013; Sato et al., 2014a; Sato et al., 2014b). Sato et al. reported that 
activated Rev-erb α repressed Il6 expression not only directly through a 
Rev-erb α binding motif but also indirectly through suppression of NF-κB 
activity (Sato et al., 2014). They also reported that Rev-erb α regulated the 
inflammatory function of macrophages through suppression of MCP1-
activating ERK and p38 signalling pathway (Sato et al., 2014). Il6 receptor 
antagonist has been reported to reduce leukocyte and macrophage 
infiltration and attenuate MMP activation, leading to a marked 
improvement in LV remodeling and survival after MI (Möllmann et al., 
2010). Moreover, targeted deletion of Mcp1 attenuated LV remodeling after 
MI through decreases in macrophage infiltration and MMP activation 
(Dewald et al., 2005; Kaikita et al., 2004). MMP9 is known as a major 
subtype of metalloproteinase and plays a crucial role in post-MI 
remodeling. In the acute inflammatory phase after MI, neutrophils and 
monocytes are considered to be the predominant source of MMPs. Higher 
production of MMPs is more likely to cause LV wall thinning and 
dilatation, consequently leading to heart failure and cardiac rupture. It has 
been reported that genetic and pharmacological deletion of Mmp9 prevents 
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adverse LV remodeling after MI (Ducharme et al., 2000; Romanic et al., 
2002). Moreover, previous study reported that Rev-erbs repressed Mmp9 
expression at a distance by regulating enhancer-directed transcription (Lam 
et al., 2013). Thus, the present study, taken together with the findings of 
previous reports, suggests that the strong inhibitory effect of SR9009 on the 
production of inflammatory cytokines such as Il6 and Mcp1 attenuates 
neutrophil and M1 macrophage infiltrations and Mmp9 production, at least 
partially through suppression of NF-κB, ERK, or p38 signalling pathway, 
leading to inhibition of the vicious circle of inflammatory amplification, the 
development of adverse LV remodeling, and cardiac rupture (Figure 18). 
MAPKs are known as important signaling pathway that regulates cell 
survival, apoptosis, and proliferation. In the present study, phosphorylated 
ERK and phosphorylated p38 were significantly decreased by SR9009 
treatment in the LV after MI. ERK activation is thought to inhibit apoptotic 
loss of cardiomyocytes and promote cardiac fibrosis. On the other hands, 
p38 activation has been implicated in the progression of apoptosis and 
cardiac dysfunction, leading to pathological remodeling although still 
controversial (Yeh et al., 2010). 
Despite a significant improvement of LV function by SR9009 
treatment, there was no significant difference in collagen deposition 
41 
 
between MI+V and MI+SR. The size of collagen deposition area is mainly 
determined by the size of the necrotic area, the wound healing response, 
and chronic remodeling (Kempf et al., 2012). Among them, the size of the 
necrotic area is the most critical for determination of the scar size in acute 
phase of MI, especially without reperfusion. Because we employed mice 
model with the permanent ligation of the proximal LAD in this study, 
necrotic area was relatively extensive and generally constant in each 
mouse. Therefore, the area of collagen deposition was mostly influenced by 
the size of necrotic area with or without treatment. However, because 
histologically-analyzing data were obtained from the samples collected 
within 1 week after MI, further studies are needed to evaluate the effect of 
Rev-erb agonist in collagen deposition in chronic phase of MI. 
Rev-erb α regulates not only inflammation but also mitochondrial 
content and oxidative capacity. It has been reported that expression levels 
of phosphorylated AMPK, SIRT1, PGC1α, and mitochondrial transcription 
factor A (TFAM) were significantly lower in the skeletal muscle from 
homogenous Nr1d1-knockout (Nr1d1-/-) mice compared to wild-type mice 
(Woldt et al., 2013). Consequently, mitochondrial DNA content was 
significantly lower in skeletal muscle from Nr1d1-/- mice, and VO2 max 
during exercise was significantly lower in Nr1d1-/- than in wild-type mice. 
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By contrast, pharmacological activation or skeletal muscle-specific Rev-erb 
α overexpression resulted in the opposite phenotypes. These findings 
suggest that Rev-erb α controls mitochondrial biogenesis and respiration in 
the skeletal muscle through the AMPK-SIRT1-PGC1α-TFAM signaling 
pathway. Several studies reported that activation of AMPK, such as 
treatment with metformin, protects the heart against cardiac stress such as 
ischemia by regulating glucose and fatty acid metabolism (Susheel et al., 
2007; Whittington et al., 2013). Therefore, favorable effects of Rev-erb 
agonist SR9009 on cardiac function may be partially attributed to 
activation of this pathway and modulation of the metabolic process 
(Jaramillo et al., 2010; Joseph Bass, 2010; Ramakrishnan et al., 2005; 
Raspé et al., 2002; Yang et al., 2013). However, we could not find 
significant increases in the expression levels of mitochondrial biogenesis-
related gene and key enzymes of cardiac metabolism between MI+V and 
MI+SR 7 days after MI. Because mitochondrial respiration is bound to be 
strongly suppressed under ischemic conditions during the acute phase of 
MI, the result seems inevitable to maintain energy metabolism during the 
acute phase of MI. Further studies are needed to clarify the effect of the 
Rev-erb agonist on cardiac metabolism after MI, especially during the 
chronic phase. 
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SR9009 and SR9011 were synthesized as novel Rev-erb agonists, and 
they have been reported to improve hyperglycemia, dyslipidemia, and 
skeletal muscle oxidative capacity by modulating mitochondrial number 
and oxidative function in mice (Woldt et al., 2013). Moreover, long-term 
treatment with SR9009 could reduce atherosclerotic plaque by decreasing 
the ratio of pro-inflammatory M1 macrophages to anti-inflammatory M2 
macrophages in LDL receptor-deficient mice fed a Western diet (Sitaula et 
al., 2015). The present study showed no apparent toxicity in consistent with 
previous study (Sitaula et al., 2015) Although we administered only one 
dose of SR9009 (100 mg/kg/day) intraperitoneal according to the previous 
study (Sitaula et al., 2015; Solt et al., 2012), we may need another dose to 
investigate whether dose dependency exists. Moreover, we tried to start the 
treatment with SR9009 on the next day after MI surgery; however, the 
survival rate and LV function did not reach significant improvement. 
Longer periods of severe ischemia (usually more than 6-hour ischemia due 
to complete coronary occlusion) is considered to cause loss of most 
cardiomyocytes in the subendocardial region of the ischemic area 
(Frangogiannis, 2015). “Late-start treatment” with SR9009 may not exert 
enough inhibitory effects on cardiac cell death although a single injection 
of 100 mg/kg of SR9009 quickly alters circadian pattern and metabolic 
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gene expressions in mice (Solt et al., 2012). Recently, Zhang et al reported 
that SR9009 ameliorated norepinephrine-induced cardiomyocyte 
hypertrophy, pressure-overloaded cardiac hypertrophy and heart failure in 
mice through transcriptional repression of the fetal gene program. They 
also showed a protective effect of SR9009 for the endothelin-1–induced 
hypertrophy using human induced pluripotent stem cell-differentiated 
cardiomyocytes (iPS-CM), just as in the rodent cardiomyocytes (Zhang et 
al., 2017). Thus, Rev-erb agonist has a direct protection in the 
cardiomyocytes in a cell-autonomous fashion, consistent with our results. 
As clinical implications, Rev-erb agonists may be useful for secondary 
prevention in patients with prior MI or metabolic syndrome with high risk 
for coronary artery disease although late-start treatment with Rev-erb 
agonist after the onset of MI may not be enough to improve clinical 
prognosis. 
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Figure 18. Schema of action of Rev-erb on post-MI remodeling.  
This schema shows possible roles of Rev-erb in post-MI remodeling. 
The strong inhibitory effect of SR9009 on the production of 
inflammatory cytokines such as IL6 and MCP1 attenuates neutrophil 
and M1 macrophage infiltrations and MMP9 production, at least 
partially through suppression of NF-κB, ERK, or p38 signalling 
pathway, leading to inhibition of the development of adverse LV 
remodeling, and cardiac rupture. However, the decreasing of IL-6 and 
MCP-1 productions or NFkb and mapks activation independently also 
may directly inhibit post MI remodeling.   
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Chapter 5 Clinical Implications 
 
 
In terms of clinical implications, the present study, taken together with the 
previous reports, suggested that Rev-erb agonists can be expected to be 
promising novel drugs not only for metabolic syndrome and atherosclerotic 
disease but also for MI and heart failure. For example, the drugs may be 
useful for secondary prevention in patients with MI complicated with 
metabolic syndrome. 
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Chapter 6 Study Limitation 
 
 
The present study included the following limitations. First, we only studied 
the acute phase of MI using a mouse model with permanent ligation of the 
coronary artery. Further studies are needed to elucidate the long-term 
effects of Rev-erb agonist and/or in an ischemia/reperfusion model. 
Second, although we administered only one dose of SR9009 (100 
mg/kg/day) according to the previous study and displayed no apparent 
toxicity (Sitaula et al., 2015; Solt et al., 2012), we may need another dose 
to investigate whether dose dependency exists. Third, recent study did not 
check the SR9009 tissue concentration or the distribution in the tissue. 
Fourth, this study suggested that the favorable effect of SR9009 on post-MI 
remodeling was mainly attributed to the strong attenuations of 
inflammatory cytokine production and MMP9 production. However, 
another mechanism such as alteration of metabolic processes and/or 
circadian rhythm may contribute to the results. Further studies are desirable 
to investigate the mechanism of the effect of Rev-erb activation on post-MI 
remodeling using antagonist or gene-manipulated mice models. 
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Chapter 7 Conclusions 
 
 
In conclusion, Rev-erb agonist SR9009 could improve cardiac function and 
survival in a mouse model of acute MI by inhibiting cytokine production 
and inflammatory cell infiltration. Rev-erb α is expected to be a promising 
therapeutic target not only for metabolic syndrome and atherosclerotic 
disease but also for MI and heart failure. 
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